stockportfolio.pro
Teleflex Incorporated (TFX)
Healthcare · Medical Instruments & Supplies · NYSE
Teleflex Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.87B | $2.15B | $2.45B | $2.60B | $2.54B | $2.81B | $2.79B | $2.97B | $3.05B | $1.98B |
| Gross profit | $996.20M | $1.17B | $1.30B | $1.41B | $1.32B | $1.55B | $1.53B | $1.04B | $1.04B | $1.12B |
| Net income | $237.38M | $152.53M | $200.80M | $461.47M | $335.32M | $485.37M | $363.14M | $356.33M | $69.67M | $-905.64M |
| Net margin | 12.7% | 7.1% | 8.2% | 17.8% | 13.2% | 17.3% | 13.0% | 12.0% | 2.3% | -45.7% |
Source: Teleflex Incorporated SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into TFX stock?
At today's market cap of $5.88B, Teleflex Incorporated is priced for free-cash-flow growth of about 91.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.45M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -66.6%/yr over the last five fiscal years and revenue -4.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Teleflex Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TFX in your portfolio →
Teleflex Incorporated financial history by metric
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Teleflex Incorporated — frequently asked questions
What is Teleflex Incorporated's revenue?
Teleflex Incorporated (TFX) reported revenue of $1.98B for fiscal year 2025, down 34.9% from the prior year, according to its SEC filings.
Is Teleflex Incorporated profitable?
No — TFX reported a net loss of $-905.64M in fiscal 2025.
What is TFX's P/E ratio?
Teleflex Incorporated trades at a price-to-earnings ratio of about 2657.2 based on the latest data in our nightly-refreshed cache.
How fast is Teleflex Incorporated growing?
TFX's revenue grew at roughly -4.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Teleflex Incorporated have?
As of fiscal year 2025, TFX carried roughly $2.74B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Teleflex Incorporated's gross margin?
TFX's gross margin was 56.5% in fiscal 2025 — gross profit of $1.12B on revenue of $1.98B.
What is Teleflex Incorporated's market cap?
Teleflex Incorporated (TFX) has a market capitalization of about $5.88B, based on the latest data in our nightly-refreshed cache.
When does Teleflex Incorporated's fiscal year end?
TFX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into TFX stock?
At today's market cap of $5.88B, Teleflex Incorporated is priced for free-cash-flow growth of about 91.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.45M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -66.6%/yr over the last five fiscal years and revenue -4.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Teleflex Incorporated's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.